Has Priyatha Garlapati, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,566 in general payments to Priyatha Garlapati, MD across 360 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Priyatha Garlapati, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Priyatha Garlapati, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Priyatha Garlapati, MD

Rheumatology · Tulsa, OKNPI 1184101313

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 360 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations.

$7,566in general payments, 2019–2025

Across 360 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Amgen$2K
UCB, Inc.$924
Pfizer$645
AstraZeneca$592
Johnson & Johnson$337
plus $2K from 15 others

What the payments were for

Food & beverage$7,38198%
Education$1852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	89	$1,758
Amgen(2 entities)	93	$1,640
UCB, Inc.	37	$924
Pfizer	30	$645
AstraZeneca	23	$592
Johnson & Johnson	11	$337
Novartis	14	$270
Mallinckrodt Hospital Products Inc.	7	$249
Lilly USA, LLC	8	$185
Aurinia Pharma U.S., Inc.	9	$157
GSK	7	$139
E.r. Squibb & Sons, L.L.C.	5	$129
Fresenius Kabi USA, LLC	7	$124
Boehringer Ingelheim	5	$93
Scilex Pharmaceuticals Inc.	2	$66
Sanofi	3	$63
Genentech USA, Inc.	4	$58
Organon	2	$49
Sandoz	2	$48
ANI Pharmaceuticals, Inc.	1	$20
Celltrion USA Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,566 in reported general payments places this provider in the 60th percentile of 67 rheumatology providers in Oklahoma.

See all rheumatology providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$31,287

Medicare patients

106

Services billed

240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	24	$269,722
Orencia ClickjectAbatacept	13	$85,771
Actemra ActpenTocilizumab	12	$54,892
Mycophenolate Mofetil	13	$2,827
MethotrexateMethotrexate Sodium	97	$1,894
Hydroxychloroquine Sulfate	41	$1,658
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	15	$682
Gabapentin	27	$665
Diclofenac Sodium	21	$576
Prednisone	65	$393
Sulfasalazine	20	$204
Celecoxib	13	$156
Folic Acid	15	$103
Alendronate Sodium	11	$91
Tizanidine Hcl	13	$48

Paid to pharmacies, not to this prescriber.

Other rheumatology in Tulsa

Debbie FoleyTulsa$281K
Mary Hinojos MamutTulsa$21K
Manuel CalvinTulsa$19K
Alan MartinTulsa$18K
William SurbeckTulsa$17K
Michael MalloyTulsa$13K
Ellen ZanetakisTulsa$10K
Basmah JalilTulsa$10K
James McKayTulsa$5K
Lindsay CunninghamTulsa$3K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →